University of Alabama
Birmingham, Alabama, 35294, United States
NCT Number: NCT01769963
The purpose of the study is to learn more about how advanced glycation end-products can affect insulin resistance, inflammation and blood vessel health in people with kidney disease.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35294, United States
Advanced glycation end-products (AGEs) are compounds that form when sugars abnormally attach to proteins or lipids. High levels of AGEs in the blood may cause inflammation, problems with controlling blood sugar, and problems with the health of blood vessels. Many of the foods we commonly eat have high amounts of AGEs, which may increase AGEs in the blood of people with kidney disease. The amount of AGEs in foods can be lowered when prepared using special cooking techniques such as using moist heat or longer cooking times at lower temperatures. New research has shown that preparing food in this way can lower inflammation and improve blood vessel health in people with normal kidney function.
In this study, the investigators would like to examine the effect of lowering the AGE content of foods on inflammation, blood sugar control, and blood vessel health in individuals with mild to moderate chronic kidney disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
Time frame: baseline, one week and three weeks
Change in CML concentrations
Time frame: baseline, one week and three weeks
Change in interleukins 1, 6 and 10, c-reactive protein
Time frame: baseline, one week and three weeks
Change in HOMA-IR
Time frame: one week and three weeks
Changes in brachial FMD
University of Alabama at Birmingham
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00374595
Avitaminosis, Cardiovascular Disease
Omaha, Nebraska, United States
View Trial DetailsNCT02113462
Chronic Disease, Chronic Kidney Disease
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05021835
Cardiovascular Risk, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT02114281
Chronic Disease, Chronic Kidney Disease
Bordeaux, France
View Trial Details